Gilotrif (Non-Small Cell Lung Cancer) – Forecast and Market Analysis to 2022 … – SBWire (press release)

by lowes1 on October 8, 2013

Gilotrif (Non-Small Cell Lung Cancer) – Forecast and Market Analysis to 2022
SBWire (press release)
Boston, MA — (SBWIRE) — 10/08/2013 — Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However 
RESEARCH AND MARKETS: Ramucirumab (Non-Small Cell Lung Cancer 4-traders (press release)

all 2 news articles »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: